144 related articles for article (PubMed ID: 8937930)
1. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment.
Derendorf H; Dalla Costa T
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):482-8. PubMed ID: 8937930
[TBL] [Abstract][Full Text] [Related]
2. Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
Dowell JA; Korth-Bradley J; Milisci M; Tantillo K; Amorusi P; Tse S
J Clin Pharmacol; 2001 Sep; 41(9):979-86. PubMed ID: 11549103
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations.
Dalla Costa T; Nolting A; Rand K; Derendorf H
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):426-33. PubMed ID: 9352391
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.
Halstenson CE; Wong MO; Johnson CA; Zimmerman SW; Onorato JJ; Keane WF; Doepner M; Sia L; Tantillo K; Bansal S
J Clin Pharmacol; 1994 Dec; 34(12):1208-17. PubMed ID: 7738217
[TBL] [Abstract][Full Text] [Related]
6. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
[TBL] [Abstract][Full Text] [Related]
8. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration.
Arzuaga A; Maynar J; Gascón AR; Isla A; Corral E; Fonseca F; Sánchez-Izquierdo JA; Rello J; Canut A; Pedraz JL
J Clin Pharmacol; 2005 Feb; 45(2):168-76. PubMed ID: 15647409
[TBL] [Abstract][Full Text] [Related]
9. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.
Newman D; Scheetz MH; Adeyemi OA; Montevecchi M; Nicolau DP; Noskin GA; Postelnick MJ
Ann Pharmacother; 2007 Oct; 41(10):1734-9. PubMed ID: 17726066
[TBL] [Abstract][Full Text] [Related]
10. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
Valtonen M; Tiula E; Takkunen O; Backman JT; Neuvonen PJ
J Antimicrob Chemother; 2001 Dec; 48(6):881-5. PubMed ID: 11733473
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
Sörgel F; Kinzig M
Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
13. Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis.
Dalla Costa T; Nolting A; Kovar A; Derendorf H
J Antimicrob Chemother; 1998 Dec; 42(6):769-78. PubMed ID: 10052901
[TBL] [Abstract][Full Text] [Related]
14. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).
van der Werf TS; Mulder PO; Zijlstra JG; Uges DR; Stegeman CA
Intensive Care Med; 1997 Aug; 23(8):873-7. PubMed ID: 9310805
[TBL] [Abstract][Full Text] [Related]
16. Biliary elimination and hepatic disposition of an association of piperacillin and tazobactam: experimental evaluation.
Brogard JM; Caro-Sampara F; Westphal JF; Blickle JF; Jehl F
Drugs Exp Clin Res; 1994; 20(6):247-55. PubMed ID: 7758397
[TBL] [Abstract][Full Text] [Related]
17. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister PD; Prevan AM; Sanders CC
Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
[TBL] [Abstract][Full Text] [Related]
19. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease.
Johnson CA; Halstenson CE; Kelloway JS; Shapiro BE; Zimmerman SW; Tonelli A; Faulkner R; Dutta A; Haynes J; Greene DS
Clin Pharmacol Ther; 1992 Jan; 51(1):32-41. PubMed ID: 1310077
[TBL] [Abstract][Full Text] [Related]
20. Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.
Auclair B; Ducharme MP
Antimicrob Agents Chemother; 1999 Jun; 43(6):1465-8. PubMed ID: 10348772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
